Close Menu

protein arrays

A UPenn research team has developed a proof-of-principle detection platform that uses microbubbles to make target protein molecules visible and detectable.

KMPJM will provide diagnostic and prognostic testing services based on genes, proteins, and other molecules to aid physicians in assessing and treating patients.

The company said that it can distinguish patients suffering from lupus from those with other autoimmune diseases using its antibody array platform.